Alnylam Pharmaceuticals (ALNY) Gross Profit (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has 9 years of Gross Profit data on file, last reported at $992.7 million in Q2 2026.

• Quarterly Gross Profit rose 57.16% year-over-year to $992.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.8 billion (up 155.4% YoY) and the FY2025 annual result came in at $3.0 billion, up 56.4% from the prior year.
• Gross Profit climbed to $992.7 million in Q2 2026, from $959.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.1 billion in Q3 2025 to a low of -$40.2 million in Q1 2025.
• A 5-year average of $490.2 million and a median of $429.3 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2025 — Gross Profit slumped 109.14% — and 2026, when it jumped 2488.21%.
• Tracing ALNY's Gross Profit over 5 years: stood at $288.9 million in 2022, then rose by 27.31% to $367.7 million in 2023, then surged by 33.39% to $490.5 million in 2024, then jumped by 69.07% to $829.3 million in 2025, then advanced by 19.7% to $992.7 million in 2026.
• The last three Gross Profit figures came in at $992.7 million (Q2 2026), $959.7 million (Q1 2026), and $829.3 million (Q4 2025), per Business Quant data.